<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445783</url>
  </required_header>
  <id_info>
    <org_study_id>CRUK-LCC-1/3/57</org_study_id>
    <secondary_id>CDR0000532934</secondary_id>
    <secondary_id>EU-20704</secondary_id>
    <nct_id>NCT00445783</nct_id>
  </id_info>
  <brief_title>Study of Families With Melanoma</brief_title>
  <official_title>Melanoma Family Case-Control Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leeds Cancer Centre at St. James's University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: A study that evaluates patients' lifestyle, skin, and blood and tissue samples may&#xD;
      help doctors understand the risk factors for melanoma relapse.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying the risk factors for melanoma in families with&#xD;
      melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine what lifestyle factors and which genes govern relapse from melanoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare sun exposure and genes that cause melanoma in patients with melanoma vs healthy&#xD;
           participants.&#xD;
&#xD;
        -  Assess how unusual moles relate to sun exposure and genes that cause melanoma.&#xD;
&#xD;
      OUTLINE: This is a multicenter, cohort study.&#xD;
&#xD;
      Patients and healthy participants complete lifestyle questionnaires by mail and telephone.&#xD;
      Some patients* and healthy participants undergo a skin examination to count moles and&#xD;
      classify skin type (e.g., degree of freckling and wrinkling indicative of sun damage).&#xD;
&#xD;
      NOTE: *Patients diagnosed with primary invasive melanoma after September 2005 do not need to&#xD;
      consent to a skin examination.&#xD;
&#xD;
      Patients and healthy participants also undergo blood collection for lymphocyte analysis, DNA&#xD;
      extraction, and the measurement of minerals, vitamins, and beta carotene. Tissue samples from&#xD;
      original diagnosis are examined by immunohistochemistry for gene expression and mutations,&#xD;
      including CDKN2A and CDK4.&#xD;
&#xD;
      Patients and healthy participants are followed annually.&#xD;
&#xD;
      Peer reviewed and funded or endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3,700 patients and healthy participants will be accrued for&#xD;
      this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2000</start_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Lifestyle factors governing relapse from melanoma</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Genes governing relapse from melanoma</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Sun exposure and genes that cause melanoma</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Unusual moles related to sun exposure and genes that cause melanoma</measure>
  </primary_outcome>
  <enrollment type="Anticipated">3700</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>examination</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>mutation carrier screening</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>study of high risk factors</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Newly diagnosed primary invasive melanoma (patient group)&#xD;
&#xD;
                    -  Lentigo maligna malignant melanoma allowed&#xD;
&#xD;
                    -  Rare variants of melanoma allowed, including any of the following:&#xD;
&#xD;
                         -  Acral lentiginous&#xD;
&#xD;
                         -  Subungual&#xD;
&#xD;
                         -  Ear, nose, and throat&#xD;
&#xD;
                         -  Oropharyngeal&#xD;
&#xD;
                         -  Perineal&#xD;
&#xD;
                         -  Vaginal&#xD;
&#xD;
                         -  Vulval&#xD;
&#xD;
                         -  Rectal&#xD;
&#xD;
                         -  Nodal with no known primary&#xD;
&#xD;
                    -  Patients undergoing sentinel node biopsy are eligible&#xD;
&#xD;
                    -  No in situ melanoma, melanocytic intraepidermal neoplasia, or ocular&#xD;
                       melanoma&#xD;
&#xD;
               -  Healthy participant meeting either of the following criteria (control group):&#xD;
&#xD;
                    -  Relative of a patient who was diagnosed with melanoma after September 2005&#xD;
&#xD;
                    -  Healthy volunteer who is age- and sex-matched for patients who were&#xD;
                       diagnosed with melanoma before October 2005&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Newton Bishop, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leeds Cancer Centre at St. James's University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-113-206-6400</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2007</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>lentigo maligna malignant melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>acral lentiginous malignant melanoma</keyword>
  <keyword>nodular malignant melanoma</keyword>
  <keyword>stage IA melanoma</keyword>
  <keyword>stage IB melanoma</keyword>
  <keyword>stage IIA melanoma</keyword>
  <keyword>stage IIB melanoma</keyword>
  <keyword>stage IIC melanoma</keyword>
  <keyword>stage IIIA melanoma</keyword>
  <keyword>stage IIIB melanoma</keyword>
  <keyword>stage IIIC melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

